Israeli Biotech Company Forges Immunotherapy Collaboration with Hadassah

Wednesday, Nov 2 2016

Vaxil Biotherapeutics Israel has signed an immunotherapy collaboration agreement with the Hadassah Medical Organization, intended to enhance the Company's immunotherapy platform, including its lead product, Immucin™. 

"I am a strong believer in Vaxil's immunotherapy platform,” relates Prof. Michael Shapira, who is spearheading the collaboration and joining Vaxil’s Scientific Advisory Board. “I have spent years following Immucin's progress, and have been fortunate to witness the promising potential both in cancer patients and in the laboratory. Hadassah is excited to be embarking on this collaboration and partnering with Vaxil's scientific team." 

Through this collaboration, Hadassah cancer patients and healthy volunteers will provide tumor samples which will be analyzed in conjunction with Vaxil's immune therapies. They will also be used in Vaxil’s investigation of potential combination therapies. The company notes that Immucin has the potential to be a very strong immunotherapy, whether as a stand-alone treatment or possibly in combination with other products.

The Vaxil and Hadassah scientists will further examine the nature of immune response to its immunotherapy in hematological patients, specifically those that are in remission from multiple myeloma and leukemia. Investigations and analysis will take place primarily at Vaxil's laboratory, using the company's fluorescence-activated cell sorting machine and other facilities. Immucin has already completed a successful Phase-I/II clinical trial, under the direction of Prof. Shapira, and will now be positioned toward a larger Phase II trial. The previous trial demonstrated the safety of Immucin and established its potential to elicit a novel specific cellular response against a highly prominent cancer target entitled MUC1-SP--a target that is present on 90 percent of all human cancers, but has proven elusive in terms of optimal treatment protocol.

This Vaxil-Hadassah partnership will investigate Immucin’s mode of action and, in turn, create an optimal design for its next clinical trial, to be launched in 2017. Learn more about immunotherapy and Immucin at https://www.youtube.com/watch?v=XhEwj6Ue13s


No comments yet.
First Name
Enter this word:

Related Stories


Friday, Jan 13 2017

Saving Children in the Nick of Time at Hadassah

When a four-year-old, blue and critically ill, was rushed into the pediatric emergency room at Hadassah Hospital Mount Scopus, Dr. David Rekhtman, head of the ER, and his team deciphered that the child had somehow consumed methadone.


Friday, Jan 13 2017

Peace in Sight: An Israeli, Palestinian, and Hadassah Australia Collaboration

St. John of Jerusalem Eye Hospital, in collaboration with Hadassah Medical Center, has received a €500,000 grant from the European Union to establish a genetic research unit to serve the Palestinian communities.


Friday, Jan 13 2017

A Second Chance at Life, Thanks to Hadassah’s Heart Institute

A resident of a rural settlement called Dishon, established by Libyan Jewish immigrants in 1953, Eyal Amar, age 47, was rather young to suffer a devastating heart attack. Nevertheless, he did, but thanks to the courage and skill of the specialists at the Hadassah Medical Organization’s Heart Institute and their complex protocol to redesign his heavily damaged heart, Eyal is able to walk and breathe again.


Tuesday, Jan 10 2017

From Locked Jaw to Osteoarthritis: Hadassah Discovery Leads to New Treatment

What began as a solution to locked jaw--temporomandibular joint (TMJ) disorder--has led to the creation of a novel non-opioid pharmaceutical candidate for the treatment of osteoarthritis pain, thanks to a Hadassah Medical Organization discovery and collaboration with colleagues at the Hebrew University and the Technion.


Donation Questions


(800) 928-0685

Membership Questions


(800) 664-5646

Missions Department


(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005


More ›

Show More